Phathom Pharmaceuticals, Inc. (PHAT) stock
Close on Nov 11, 2026Market cap $510.51MP/E –Yield –
Phathom Pharmaceuticals, Inc. grew revenue 86.8% to $274.88M over the twelve months to Sep 30, 2026. Free cash flow was -$21.04M. At the latest close the market valued the company at $510.51M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $510.51M
- P/E ratio
- –
- Price to sales
- 1.86
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -4.12%
Fundamentals
- Revenue
- $274.88M
- Net income
- -$83.00M
- EPS, diluted
- -$1.03
- Free cash flow
- -$21.04M
- Book value per share
- -$4.10
- Diluted shares
- 85M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $5.45
- Open
- $5.45
- Day's range
- $5.40 – $6.32
- Volume
- 1,572,810
- Average volume (20 days)
- 1,863,272
- Index membership
- Russell 2000 (since Dec 2019), Russell 3000 (since Feb 2020)
- Beta (5 years)
- 1.63
- 52-week range
- $5.01 – $18.31
- RSI (14 days)
- 49.5
- Volatility (1 year)
- 69.4%
- Relative volume
- 1.05×
- WACC
- 12.7%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PHAT | S&P 500 | Difference | PHAT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -13.4% | -2.4% | −11.0 pts | ||
| 3 months | -26.2% | -1.2% | −25.1 pts | ||
| Year to date | -62.1% | +12.3% | −74.4 pts | ||
| 1 year | -56.3% | +12.4% | −68.7 pts | ||
| 3 years | -16.4% | +78.8% | −95.2 pts | -5.8% | +21.4% |
| 5 years | -71.5% | +75.2% | −146.6 pts | -22.2% | +11.9% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Phathom Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- News
About Phathom Pharmaceuticals
Pharmaceutical Preparations
Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to commercializing and developing therapeutic treatments for gastrointestinal diseases. The company offers vonoprazan-based acid blockers, including VOQUEZNA tablets for gastroesophageal reflux disease indications such as Erosive GERD and Non-Erosive GERD heartburn, as well as combination therapies for Helicobacter pylori infection alongside antibiotics under the brands VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK. Its primary customers are patients prescribed therapies for gastrointestinal conditions through healthcare providers such as gastroenterologists.
Company profile, executives and historyPhathom Pharmaceuticals stock: common questions
What is Phathom Pharmaceuticals's stock price?
PHAT closed at $6.28 on Nov 11, 2026, up 15.34% on the day. Over the past 52 weeks it traded between $5.01 and $18.31.
What is Phathom Pharmaceuticals's market cap?
Phathom Pharmaceuticals was worth $510.51M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PHAT's P/E ratio?
Phathom Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.03), so it has no meaningful P/E ratio.
How much revenue does Phathom Pharmaceuticals make?
Phathom Pharmaceuticals reported revenue of $274.88M for the twelve months to Sep 30, 2026, up 86.8% from a year earlier.
Does Phathom Pharmaceuticals pay a dividend?
No. Phathom Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Phathom Pharmaceuticals report earnings next?
Phathom Pharmaceuticals is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has PHAT stock performed over the past year?
Including dividends, PHAT returned -56.3% over the past year, against +12.4% for the S&P 500.
How many PHAT shares are sold short?
9M shares were sold short at the latest FINRA report, 12.89% of the float, or 4.8 days of average trading volume.
Who are Phathom Pharmaceuticals's competitors?
Companies most similar to Phathom Pharmaceuticals by business, industry and size include SNDX, AKBA, RIGL, ARDX, IRWD.
See a number that looks wrong?